A study published in Diabetes Therapy found that vildagliptin significantly reduces the risk of hypoglycemia in type 2 diabetes mellitus (T2DM) patients fasting during Ramadan, compared to sulfonylureas (SUs). Among 246 patients analyzed, only 1.7% of those receiving vildagliptin experienced a hypoglycemic event, compared with 19.2% in the SU group.
The 16‑week prospective study included patients on vildagliptin or SU, either as monotherapy or combined with metformin, with data collected before, during, and after Ramadan. Vildagliptin also showed modest benefits in glycemic control and body weight, with a mean HbA1c reduction of −0.1% versus a rise of 0.3% in the SU group, and a mean weight reduction of 0.8 kg compared to 0.1 kg. The findings suggest vildagliptin offers a safer alternative for T2DM patients observing fasting.
Select Content Type
Resources
Interests
Cardiology
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pediatric Medicine
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Speciality
Cardiology
Dentistry
Dermatology
Emergency Medicine
Endocrinology
ENT
Gastroenterology
Geriatrics
Hematology
Immunology Allergy & Inflammation
Infectious Disease & Vaccines
Internal/Family Medicine
Medical Genetics
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Orthopedic
Pain & Anesthesiology
Pathology
Pediatric Medicine
Pharmacology
Psychiatry
Public Health
Pulmonology
Radiology
Rheumatology
Surgery
Urology & Nephrology
Thumbnail Image
Detail Image
Book Detail
Upload PDF
EFFECT_1.PDF
(497.13 KB)
Actions
Download in App
Countries of release
India
Nigeria
UAE
IS_Ebsco
false
Description